Vol 66, No 2 (2015)
Original paper
Published online: 2015-05-01

open access

Page views 2838
Article views/downloads 4953
Get Citation

Connect on Social Media

Connect on Social Media

Radioiodine therapy for Graves’ disease — retrospective analysis of efficacy factors

Piotr Szumowski, Saeid Abdelrazek, Agnieszka Kociura Sawicka, Małgorzata Mojsak, Jerzy Kostecki, Monika Sykała, Janusz Myśliwiec
DOI: 10.5603/EP.2015.0019
Pubmed: 25931042
Endokrynol Pol 2015;66(2):126-131.


Introduction: Radioiodine (131I) isotope therapy is the method of choice in the treatment of Graves’ disease relapse. The efficiency of this method is dependent on many factors; therefore, the present paper aims to identify the parameters that have a crucial impact on the efficacy of radioiodine therapy for Graves’ disease.
Material and methods: The authors performed a retrospective analysis of the medical documentation of 700 Graves’ disease sufferers treated with131I. The patients were divided into three groups depending on the thyroid-absorbed dose of 131I: group I — 100 Gy, II — 150 Gy, and III — 200 Gy. The authors assessed the influence of gender, age, presence of orbitopathy, TRab titres, thyroid mass, iodine uptake after 24 and 48 hours, and the absorbed dose on the treatment efficacy at one year post-131I administration.
Results: The volume of thyroid gland (P < 0.002) and the thyroid-absorbed dose (P < 0.001) were the only factors that had a significant impact on the outcome of the treatment. The likelihood of hyperthyroidism persisting (odds ratio: 3.71, 95% confidence interval: 2.4–5.87) was greatest in patients from group I. In group II, with thyroid volume amounting both to 25 mL and to 25–50 mL, the percentage of hyperthyroidism was lowest (1 and 0%). However, with thyroid volume > 50 mL, the percentage of hyperthyroidism was lowest in group III (10%).
Conclusions: The absorbed dose of 131I and the volume of the thyroid gland are two parameters that have a significant influence on the efficacy of radioiodine therapy for Graves’ disease. 150 Gy is the optimal dose for glands < 50 mL. A goitre > 50 mL requires an absorbed dose of 200 Gy in order to minimise the risk of recurrent hyperthyroidism. (Endokrynol Pol 2015; 66 (2): 126–131)